Patents by Inventor William A. Kinney

William A. Kinney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20200368182
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: January 27, 2020
    Publication date: November 26, 2020
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • DEUTERATED FORMS OF AMINOSTEROLS AND METHODS OF USING THE SAME
    Publication number: 20200262864
    Abstract: Described are deuterated forms of aminosterols, or a pharmaceutically acceptable salt thereof, wherein one or more hydrogen atoms at one or more positions selected from C1, C2, C3, C4, C5, C6, C7, C8, C9, C11, C12, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, and C27, are replaced with deuterium.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 20, 2020
    Applicant: Enterin, Inc.
    Inventors: Denise Barbut, Michael Zasloff, William A. Kinney, Stephen Jones, Scott Ashford, Anton Bieliauskas, Edward Hessler, Tom Fevig, Harold Karnes
  • ALDEHYDE CONJUGATES AND USES THEREOF
    Publication number: 20200246345
    Abstract: The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: October 3, 2019
    Publication date: August 6, 2020
    Inventors: Todd Brady, Scott Young, William A. Kinney
  • DEUTERATED COMPOUNDS AND USES THEREOF
    Publication number: 20200199075
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 25, 2020
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • Toxic aldehyde related diseases and treatment
    Patent number: 10588874
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: March 17, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Deuterated compounds and uses thereof
    Patent number: 10550085
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: February 4, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • Toxic aldehyde related diseases and treatment
    Patent number: 10543181
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: January 28, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20190247334
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: February 15, 2019
    Publication date: August 15, 2019
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • SUBSTITUTED AMINOTHIAZOLES
    Publication number: 20190241552
    Abstract: Described herein are substituted aminothiazoles, compositions comprising same; and methods of making and using same.
    Type: Application
    Filed: July 11, 2017
    Publication date: August 8, 2019
    Inventors: Yanming DU, Huagang LU, John ROGOWSKY, William A. KINNEY, Andrea CUCONATI
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20190231715
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: January 30, 2019
    Publication date: August 1, 2019
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION
    Publication number: 20190125729
    Abstract: The present invention is directed to compounds of formula (A): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.
    Type: Application
    Filed: October 23, 2018
    Publication date: May 2, 2019
    Inventors: John Clifford Chabala, Thomas A. Jordan, Ke-Qing Ling, John G. Gleason, William A. Kinney
  • Toxic aldehyde related diseases and treatment
    Patent number: 10213395
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: February 26, 2019
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • MODULATION OF HEPATITIS B VIRUS CCCDNA TRANSCRIPTION
    Publication number: 20180369323
    Abstract: The present invention provides small molecule inhibitors of hepatitis B virus (HBV) covalently closed circular (ccc) DNA, which are useful as therapeutics in the management of chronic HBV. The compounds of the invention achieve epigenetic modification of the cccDNA, histone modification and histone deacetylase activity inhibition, thus modulating HBV cccDNA. The present invention further provides methods for modulating HBV cccDNA, for treating or preventing HBV in a subject, and for modulating cccDNA transcription of hepatitis B in a subject.
    Type: Application
    Filed: August 28, 2018
    Publication date: December 27, 2018
    Inventors: JU-TAO GUO, JINHONG CHANG, TIMOTHY M. BLOCK, WILLIAM A. KINNEY, HAROLD R. ALMOND
  • DEUTERATED COMPOUNDS AND USES THEREOF
    Publication number: 20180354905
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: August 22, 2016
    Publication date: December 13, 2018
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • Modulation of hepatitis B virus cccDNA transcription
    Patent number: 10143720
    Abstract: The present invention provides small molecule inhibitors of hepatitis B virus (HBV) covalently closed circular (ccc) DNA, which are useful as therapeutics in the management of chronic HBV. The compounds of the invention achieve epigenetic modification of the cccDNA, histone modification and histone deacetylase activity inhibition, thus modulating HBV cccDNA. The present invention further provides methods for modulating HBV cccDNA, for treating or preventing HBV in a subject, and for modulating cccDNA transcription of hepatitis B in a subject.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: December 4, 2018
    Assignees: Drexel University, Baruch S. Blumberg Institute
    Inventors: Ju-Tao Guo, Jinhong Chang, Timothy M. Block, William A. Kinney, Harold R. Almond
  • Traps in the treatment of macular degeneration
    Patent number: 10111862
    Abstract: The present invention is directed to compounds of formula (A): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: October 30, 2018
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: John Clifford Chabala, Thomas A. Jordan, Ke-Qing Ling, John G. Gleason, William A. Kinney
  • ALDEHYDE CONJUGATES AND USES THEREOF
    Publication number: 20180250306
    Abstract: The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: August 22, 2016
    Publication date: September 6, 2018
    Inventors: Todd Brady, Scott Young, William A. Kinney
  • DRUG DELIVERY AND IMAGING CHEMICAL CONJUGATE, FORMULATIONS AND METHODS OF USE THEREOF
    Publication number: 20180162869
    Abstract: The present invention relates to compounds, and methods of use thereof, capable of entering macrophages. The invention further relates to compounds capable of modulating (for example inhibiting) the activity of the mammalian target of rapamycin (mTor), treating mTor-associated diseases, in particular, but not limited to, related to mTor in macrophages. The invention also relates to compounds capable of imaging mTor in a subject, in particular, but not limited to, mTor in macrophages.
    Type: Application
    Filed: June 15, 2016
    Publication date: June 14, 2018
    Inventors: Steven Jay Adelman, H. Donlon Skerrett, William A. Kinney
  • MODULATION OF HEPATITIS B VIRUS CCCDNA TRANSCRIPTION
    Publication number: 20170296619
    Abstract: The present invention provides small molecule inhibitors of hepatitis B virus (HBV) covalently closed circular (ccc) DNA, which are useful as therapeutics in the management of chronic HBV. The compounds of the invention achieve epigenetic modification of the cccDNA, histone modification and histone deacetylase activity inhibition, thus modulating HBV cccDNA. The present invention further provides methods for modulating HBV cccDNA, for treating or preventing HBV in a subject, and for modulating cccDNA transcription of hepatitis B in a subject.
    Type: Application
    Filed: April 10, 2017
    Publication date: October 19, 2017
    Inventors: JU-TAO GUO, JINHONG CHANG, TIMOTHY M. BLOCK, WILLIAM A. KINNEY, HAROLD R. ALMOND
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20170239196
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: May 9, 2017
    Publication date: August 24, 2017
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell